Arcus Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flow from operating activities | ||
| Net loss | $(97) | $(155) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 40 | 37 |
| Depreciation and amortization | 5 | 4 |
| Noncash lease expense | 4 | 4 |
| Impairment of long-lived assets | 20 | — |
| Amortization of discounts on marketable securities | (13) | (8) |
| Other items, net | 1 | 1 |
| Changes in operating assets and liabilities: | ||
| Receivable from collaboration partners ($6 and $7 from a related party) | 20 | 4 |
| Other assets ($6 and ($3) from a related party) | 15 | (1) |
| Accounts payable | (1) | (9) |
| Deferred revenue (($90) and ($19) to a related party) | (81) | (19) |
| Other liabilities | (9) | (13) |
| Net cash used in operating activities | (96) | (155) |
| Cash flow from investing activities | ||
| Purchases of marketable securities | (593) | (393) |
| Proceeds from maturities of marketable securities | 484 | 542 |
| Proceeds from sales of marketable securities | 7 | 14 |
| Purchases of property and equipment | (4) | (8) |
| Net cash provided by (used in) investing activities | (106) | 155 |
| Cash flow from financing activities | ||
| Proceeds from issuance of common stock ($228 and $20 from a related party) | 228 | 20 |
| Proceeds from issuance of common stock pursuant to equity award plans | 4 | 4 |
| Payments of employee taxes related to net settlement of equity awards | (1) | — |
| Net cash provided by financing activities | 231 | 24 |
| Net increase in cash, cash equivalents and restricted cash | 29 | 24 |
| Cash, cash equivalents and restricted cash at beginning of period | 130 | 209 |
| Cash, cash equivalents and restricted cash at end of period | $159 | $233 |
| Non-cash investing and financing activities: | ||
| Unpaid portion of property and equipment purchases included in Accounts payable and Other current liabilities | $— | $8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.